The concern of generic rivalry has repeatedly loomed over copyright’s blockbuster drug, Viagra, sparking questions about the future of connected medicinal ventures. While first years saw substantial profits, the exclusivity end has created the path for discounted alternatives, potentially lowering profitability and creating a genuine danger for s